Abstract 2563: Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies

嵌合抗原受体 癌症研究 受体 免疫学 过继性细胞移植 医学 T细胞 生物 免疫系统 内科学
作者
Edwin J. Velazquez,John Lattin,Taylor D. Brindley,Zachary Z. Reinstein,Roger Chu,Lu Liu,Evita G. Weagel,Michelle H. Townsend,Kiara V. Whitley,Eliza L. Lawrence,Brandon T. Garcia,Scott Weber,Richard A. Robison,Kim L. O’Neill
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (13_Supplement): 2563-2563 被引量:14
标识
DOI:10.1158/1538-7445.am2018-2563
摘要

Abstract Recent clinical trials using chimeric antigen receptors (CAR) T cells have demonstrated tremendous success in eradicating hematologic malignancies. Notwithstanding the excitement generated by CAR T cell therapy, its clinical efficacy has not been effectively translated to the context of solid tumors; the physical barriers of solid malignancies and the immunosuppressive conditions at the tumor site hinder the efficacy of CAR T cells. Macrophages have the ability to infiltrate almost every tissue and frequently are recruited into tumors. Therefore, macrophages are an attractive vehicle for CAR therapy and could help solve current challenges that CAR T cells face in the treatment of solid tumors. MOTO-CAR cells are monocyte-derived human macrophages that are genetically modified by a lentiviral or adenoviral approach to express a synthetic tumor-targeting receptor and to secrete cytokines, ligands or chemokine receptors. MOTO-CAR receptors are composed of a single-chain variable fragment (ScFv) that binds to a specific tumor target, a hinge to link it to a transmembrane domain, and an engineered Toll/Interleukin-1 receptor (TIR) signaling domain. When the ScFv binds to the tumor cell via its tumor target, an activation signal is transmitted. Myd88 dependent and independent signaling cascades are elicited, activating the macrophage and polarizing it towards a proinflammatory phenotype to eliminate cancer cells in a selective way. We previously reported the expression of Thymidine Kinase 1 (TK1) on the cell membrane of the non-small cell lung carcinoma NCI-H460 and A549 cell lines. The in vitro function of TK1 MOTO-CAR cells was evaluated against these cancer cell lines, using GFP-based phagocytosis and killing assays. Additionally, cell migration and interaction was recorded using time-lapse video with a confocal microscope. Upon co-culturing, with its target TK1 specific MOTO-CARs showed a nearly 4-fold increase in killing activity when compared with the controls (p<0.01). MOTO-CAR cells were produced through a lentiviral approach with around 30% of the cells expressing MOTO-CARs and with an adenoviral approach using the Ad5f35 vector with an efficiency of 70-80% of cells being transduced. Furthermore, after transduction MOTO-CAR cells showed a consistent M1 phenotype expressing high levels of CD14, CD80, CD206 and low levels of CD163. Time-lapse videos showed migration and clustering of MOTO-CAR cells around H460 GFP + cells. Moreover, cell death was observed upon contact of MOTO-CAR cells with target cells as well as phagocytic activity. In vivo testing using an orthotopic NOD scid gamma mice model is in progress. Our preclinical data show evidence that human macrophages are a suitable vehicle for CAR therapy and have the potential to successfully extrapolate the clinical efficacy of CAR therapy to the context of solid tumors. Citation Format: Edwin J. Velazquez, John E. Lattin, Taylor D. Brindley, Zachary Z. Reinstein, Roger Chu, Lu Liu, Evita G. Weagel, Michelle H. Townsend, Kiara V. Whitley, Eliza L. Lawrence, Brandon T. Garcia, Scott Weber, Richard A. Robison, Kim L. O'Neill. Macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2563.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小宋完成签到,获得积分10
刚刚
沉默的谷秋完成签到,获得积分10
刚刚
既然发布了新的文献求助10
1秒前
诚心的冬亦完成签到,获得积分10
2秒前
言言右完成签到,获得积分10
5秒前
万能图书馆应助大方乐驹采纳,获得10
6秒前
激情的鼠标完成签到,获得积分10
6秒前
8秒前
datang完成签到,获得积分10
8秒前
9秒前
Febrine0502完成签到,获得积分10
9秒前
9秒前
丘比特应助尊敬秋双采纳,获得10
10秒前
10秒前
zhang完成签到,获得积分10
11秒前
风信子完成签到 ,获得积分0
13秒前
13秒前
XRWei发布了新的文献求助10
13秒前
隐形水云完成签到 ,获得积分10
14秒前
丫丫完成签到,获得积分10
16秒前
16秒前
16秒前
16秒前
CodeCraft应助sing采纳,获得10
17秒前
是莉莉娅发布了新的文献求助30
17秒前
了0完成签到 ,获得积分10
17秒前
飞快的咖啡豆Evil完成签到 ,获得积分10
18秒前
20秒前
21秒前
GXY完成签到,获得积分10
21秒前
jing111完成签到,获得积分10
23秒前
23秒前
24秒前
24秒前
micaixing2006完成签到,获得积分10
25秒前
鲤鱼初柳发布了新的文献求助10
25秒前
26秒前
打打应助激动的xx采纳,获得10
26秒前
康师傅冰红茶完成签到,获得积分10
26秒前
科研通AI5应助Llllll采纳,获得30
28秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571662
求助须知:如何正确求助?哪些是违规求助? 3142176
关于积分的说明 9445995
捐赠科研通 2843587
什么是DOI,文献DOI怎么找? 1562944
邀请新用户注册赠送积分活动 731458
科研通“疑难数据库(出版商)”最低求助积分说明 718551